

ASX Announcement

Melbourne, Australia, 11 April 2024

Results of 2024 General Meeting

Exopharm Limited (**Exopharm** or the **Company**) is pleased to advise that Shareholders of the Company passed at the General Meeting held today at 2.00pm (AEST) all Resolutions by poll as set out in the Notice of Meeting announced to the ASX on 13 March 2024.

In accordance with ASX Listing Rule 3.13.2 and Section 251 AA(2) of the Corporations Act, a summary of the proxy votes and the number of votes cast on each resolution in the poll is **attached**.

Following today's approval by Shareholders of Resolution 16 (Approval of Change of Company Name), the Company will now undertake steps to change the Company's name and ASX Ticker with ASIC and ASX. The Company will provide further details of the name and ASX Ticker change in due course.

In addition, the Company will confirm when completion of the Arrangement Agreement with Tryp Therapeutics Inc. (**Completion**) occurs, including:

- Appointment of Directors Mr Jason Carroll, Mr Peter Molloy, Mr Gage Jull and Mr Chris Ntoumenopoulos;
- Resignation of Director Dr Ian Dixon; and
- Issue of securities under the Prospectus dated 28 March 2024.

—ENDS—

This announcement was authorised for issue by the Company Secretary of Exopharm Limited.

For more information, please contact:

Company enquiries

David Franks
Company Secretary
Exopharm Limited
P: +61 2 8098 1169

Corporate enquiries

Cameron Bolton
Alto Capital
P: +61 418 944 611

About Exopharm Limited

Exopharm (ASX:EX1) is a leader in advancing Genetic Medicines and other exosome-based medicines using exosomes or extracellular vesicles (EVs) as a chassis for improved and nonviral drug-delivery.

Exosomes can be loaded with a variety of active pharmaceutical ingredients (APIs) and can be targeted to selected cell-types and tissue types, improving the safety-profile of the APIs and providing better treatments. Exosomes can be used to deliver small molecule drugs, mRNA, DNA and other types of APIs.

Exosomes are an alternative means of drug-delivery inside the body, alongside technologies such as lipid nanoparticles (LNP), cell-penetrating peptides, viral vectors and liposomes. Exopharm's exosome technologies solve important needs for the success of exosome medicines – LEAP manufacturing technology, LOAD API loading technologies and EVPS tropism technologies.

Exosome-based medicines could improve the treatment of many chronic or inherited medical conditions. Exopharm is making its proprietary technologies available to pharmaceutical and biotechnology companies that want to harness exosome-delivery for their own products. Exopharm is also seeking to develop important exosome medicines itself.

Forward Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices or potential growth of Exopharm Limited, are, or may be, forward looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results and developments may differ materially from those expressed or implied by these forward-looking statements depending on a variety of factors.

Disclosure of Proxy Votes

Exopharm Limited

General Meeting

Thursday, 11 April 2024



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Consolidation of Capital	P	66,514,099	59,572,246 89.56%	6,862,653 10.32%	0	79,200 0.12%	59,651,446 89.68%	6,862,653 10.32%	0	Passed
2 Approval to change in nature and scale of activities	P	66,514,099	59,875,617 90.02%	6,559,282 9.86%	0	79,200 0.12%	59,954,817 90.14%	6,559,282 9.86%	0	Passed
3 Election of Director – Jason Carroll	P	66,497,405	59,848,860 90.00%	6,571,498 9.88%	16,694	77,047 0.12%	59,925,907 90.12%	6,571,498 9.88%	16,694	Passed
4 Election of Director – Peter Molloy	P	66,497,405	59,837,050 89.98%	6,583,308 9.90%	16,694	77,047 0.12%	59,914,097 90.10%	6,583,308 9.90%	16,694	Passed
5 Election of Director – Gage Jull	P	66,497,405	59,837,050 89.98%	6,583,308 9.90%	16,694	77,047 0.12%	59,914,097 90.10%	6,583,308 9.90%	16,694	Passed
6 Election of Director – Chris Ntoumenopoulos	P	66,497,405	59,848,860 90.00%	6,571,498 9.88%	16,694	77,047 0.12%	59,925,907 90.12%	6,571,498 9.88%	16,694	Passed
7 Approval to issue Public Offer Shares	P	60,952,872	54,285,670 89.06%	6,588,002 10.81%	228,227	79,200 0.13%	54,364,870 89.19%	6,588,002 10.81%	228,227	Passed
8A Participation in Public Offer by the Participating Directors – Mr Chris Ntoumenopoulos	P	66,265,872	59,583,270 89.92%	6,603,402 9.97%	248,227	79,200 0.12%	59,662,470 90.03%	6,603,402 9.97%	248,227	Passed



Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
8B Participation in Public Offer by the Participating Directors – Mr Jason Carroll	P	66,265,872	59,583,270 89.92%	6,603,402 9.97%	248,227	79,200 0.12%	59,662,470 90.03%	6,603,402 9.97%	248,227	Passed
8C Participation in Public Offer by the Participating Directors – Mr Mark Davies	P	66,265,872	59,355,270 89.57%	6,831,402 10.31%	248,227	79,200 0.12%	59,434,470 89.69%	6,831,402 10.31%	248,227	Passed
8D Participation in Public Offer by the Participating Directors – Mr Clarke Bartow	P	66,245,872	59,335,270 89.57%	6,831,402 10.31%	248,227	79,200 0.12%	59,414,470 89.69%	6,831,402 10.31%	248,227	Passed
9 Approval to issue Consideration Securities	P	66,265,872	59,355,270 89.57%	6,831,402 10.31%	248,227	79,200 0.12%	59,434,470 89.69%	6,831,402 10.31%	248,227	Passed
10A Approval of issue of Director Consideration Securities - Mr Jason Carroll	P	66,494,099	59,585,650 89.61%	6,855,449 10.31%	20,000	53,000 0.08%	59,638,650 89.69%	6,855,449 10.31%	20,000	Passed
10B Approval of issue of Director Consideration Securities – Mr Peter Molloy	P	66,494,099	59,585,650 89.61%	6,855,449 10.31%	20,000	53,000 0.08%	59,638,650 89.69%	6,855,449 10.31%	20,000	Passed
10C Approval of issue of Director Consideration Securities – Mr Gage Jull	P	66,494,099	59,585,650 89.61%	6,855,449 10.31%	20,000	53,000 0.08%	59,638,650 89.69%	6,855,449 10.31%	20,000	Passed
10D Approval of issue of Director Consideration Securities – Mr Chris Ntoumenopoulos	P	66,494,099	59,585,650 89.61%	6,855,449 10.31%	20,000	53,000 0.08%	59,638,650 89.69%	6,855,449 10.31%	20,000	Passed
11 Approval to issue Debenture Securities	P	66,265,872	59,562,623 89.88%	6,624,049 10.00%	248,227	79,200 0.12%	59,641,823 90.00%	6,624,049 10.00%	248,227	Passed
12 Approval to issue Director Debenture Securities	P	66,265,872	59,588,823 89.92%	6,624,049 10.00%	248,227	53,000 0.08%	59,641,823 90.00%	6,624,049 10.00%	248,227	Passed
13 Approval to issue Conversion Securities	P	64,569,099	57,862,450 89.61%	6,627,449 10.26%	20,000	79,200 0.12%	57,941,650 89.74%	6,627,449 10.26%	20,000	Passed
14 Approval to issue Director Conversion Securities	P	66,494,099	59,813,650 89.95%	6,627,449 9.97%	20,000	53,000 0.08%	59,866,650 90.03%	6,627,449 9.97%	20,000	Passed
15 Approval to issue Lead Manager Options	P	65,489,405	58,787,450 89.77%	6,622,755 10.11%	24,694	79,200 0.12%	58,866,650 89.89%	6,622,755 10.11%	24,694	Passed



			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
16 Approval of change of Company name	P	66,253,872	59,566,040 89.91%	6,634,832 10.01%	260,227	53,000 0.08%	59,619,040 89.99%	6,634,832 10.01%	260,227	Passed
17 Approval of New Plan	P	66,474,099	59,838,007 90.02%	6,583,092 9.90%	20,000	53,000 0.08%	59,891,007 90.10%	6,583,092 9.90%	20,000	Passed
18 Approval of potential termination benefits under the New Plan	P	66,261,178	59,393,686 89.64%	6,814,492 10.28%	252,921	53,000 0.08%	59,446,686 89.72%	6,814,492 10.28%	252,921	Passed

